KRAS P.G12C MUTANT ADVANCED SOLID TUMORS

Clinical trials for KRAS P.G12C MUTANT ADVANCED SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new KRAS P.G12C MUTANT ADVANCED SOLID TUMORS trials appear

Sign up with your email to follow new studies for KRAS P.G12C MUTANT ADVANCED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for 'Undruggable' cancer mutation

Disease control Ongoing

This study is testing a new drug called sotorasib for people with advanced solid tumors that have a specific genetic change called KRAS p.G12C. The main goals are to find a safe dose and see how well the body handles the drug. Researchers also want to learn if the drug can help s…

Matched conditions: KRAS P.G12C MUTANT ADVANCED SOLID TUMORS

Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

KRAS P.G12C MUTANT ADVANCED SOLID TUMORS

Get alerted when new KRAS P.G12C MUTANT ADVANCED SOLID TUMORS trials appear

New hope for 'Undruggable' cancer mutation